U.S. markets closed

Lannett Company, Inc. (LCI)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
4.5600-0.2900 (-5.98%)
At close: 4:00PM EDT
Sign in to post a message.
  • C
    China Joe Is Not My President
    Make sure to put high limit orders on your shares to protect them from shorting
  • a
    almlk
    It will go UP above $5 tomorrow...Shorts will start covering soon, imho. They are human too, afraid to lose profit!
    Bullish
  • T
    THT
    Extremely poor performance. Missed revenue by $4 mln. Loosing sales almost for all indications. Interest increased by nearly $20 mln. Debt increased. No new ANDA submission. Relying only to advair and insulin, which may not materialize. I am not sure why everybody in this board is so encouraged?
  • C
    China Joe Is Not My President
    8.5M shares short and it doesn't move after beating earnings and meeting revenue. Could be set up for a M&A play. Just bought more.
    Bullish
  • T
    THT
    In best case scenario predicted EPS for 2022 is $0.18. Considering falling sales, uncertainty with new ANDA approvals, even $2 is too optimistic for LCI SP.
  • F
    Fred
    Not a lot of movement after hours, probably still hold rating for awhile. I feel comfortable picking more shares under $5.
  • T
    Tom
    Good report and execution! Beat EPS nicely (2c vs -4c est) Plus POSITIVE CASH FLOW. Cash is now MORE THAN $80M...Impressive! It should go up tomorrow to $5's and $6's short term.
  • C
    Chuck
    3 year low today. Awesome!
  • T
    THT
    If believe to previous CC, Q3 sales will be disastrous

    Tim: “Meanwhile, our near term competitive environment remains challenging in part due to reduce sales from particularly profitable products. For example, Numbrino is affected by fewer elective surgeries during the pandemic. And we experienced an API disruption on the product called Metaxalone. We expect both products to contribute significantly more in each quarters than they will have the balance of this fiscal year. More significantly, we now also expect the new competitive for both Posaconazole and Fluphenazine to occur in this third quarter.”
  • A
    AMMAR
    PHILADELPHIA, April 28, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 third quarter on Wednesday, May 5, 2021, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions.
  • A
    A. Luis
    Someone on this blog advised we should sell 5 April Puts. Glad I didn’t take that advice !!
  • T
    Tom
    The management knows what they are doing, particularly the debt structure....It will go back up to 6's short term...
    Bullish
  • A
    A. Luis
    Being an unrepentant optimist, I placed an order to buy at market another 1200 shares at today’s open. Could not resist at this price. Will open my eyes and look in 30 days.
  • D
    Drakkon
    Bought this at mid 5's and really regret it. This seems headed towards zero if it can't at least hold $4.70. It fell almost 5% today when most everything else was green, so it looks like the bears are in control for now.
    Bearish
  • L
    LU
    There were two companies that filed for BK while trying to get into the insulin market, both were set up by former Lilly employee and went far ahead of where LCI is right now. These two companies are not far away from Seymor - where LCI's factories are and LCI might hired people and/or bought equipment from them. Even if LCI can come up with an insulin generic it will not make them any money - it will actually cost them big as they try to market it
  • C
    Chuck
    Very few longs who own LCI at this point are up. probably less than 1%. The chart speaks for itself.
  • A
    AMMAR
    let us take a break.
  • T
    THT
    After Q2 cash was $34m and debt was $629m. It will be interesting to see numbers after Q3 report
  • L
    LU
    There is a pandemic going on and LCI somehow just can't find a way to get involved.
    There is no future in insulin biosimilar for them, absolutely zip!! Lilly's insulin/fast acting insulin went into generic years ago but it still has a firm grip on those sales, not to mention the big dog in the cage - Novo.
    insulin itself is selling for pennies, Lilly can charge a lofty price for their (fast acting)insulin because it is delivered by a pen, even if LCI comes out with a product (that is a big if) the patient choses to buy it will have to stab themselves with a needle - not a picture that LCI investors want to envision. Do the management know this? of course they do, do they care? of course they don't
  • D
    Dookie
    Only good stock today